Mayo Clinic Proceedings Home

Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy

      Abstract

      MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

      Abbreviations and Acronyms:

      ASCT (autologous stem cell transplant), Edm (Edmonston), FDG (fluorodeoxyglucose), GFP (green fluorescent protein), M-protein (monoclonal protein), MM (multiple myeloma), MV (measles virus), MV-NIS (measles virus encoding human sodium iodide symporter), NIS (sodium iodide symporter), OV (oncolytic virus), PET (Positron emission tomography), PRN (plaque reduction neutralization), SPECT (single-photon emission computed tomography), TCID50 (50% tissue culture infectious dose)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and PersonalCorporate R&D Professionals
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Russell S.J.
        • Peng K.W.
        • Bell J.C.
        Oncolytic virotherapy.
        Nat Biotechnol. 2012; 30: 658-670
        • Vacchelli E.
        • Eggermont A.
        • Sautès-Fridman C.
        • et al.
        Trial watch: oncolytic viruses for cancer therapy.
        Oncoimmunology. 2013; 2: e24612
        • Tong A.W.
        • Senzer N.
        • Cerullo V.
        • Templeton N.S.
        • Hemminki A.
        • Nemunaitis J.
        Oncolytic viruses for induction of anti-tumor immunity.
        Curr Pharm Biotechnol. 2012; 13: 1750-1760
        • Kyle R.A.
        • Rajkumar S.V.
        An overview of the progress in the treatment of multiple myeloma.
        Exp Rev Hematol. 2014; 7: 5-7
        • Dingli D.
        • Peng K.W.
        • Harvey M.E.
        • et al.
        Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.
        Blood. 2004; 103: 1641-1646
        • Bellini W.J.
        • Rota J.S.
        • Rota P.A.
        Virology of measles virus.
        J Infect Dis. 1994; 170: S15-S23
        • Myers R.M.
        • Greiner S.M.
        • Harvey M.E.
        • et al.
        Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
        Clin Pharmacol Ther. 2007; 82: 700-710
        • Ong H.T.
        • Timm M.M.
        • Greipp P.R.
        • et al.
        Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.
        Exp Hematol. 2006; 34: 713-720
        • Ong H.T.
        • Hasegawa K.
        • Dietz A.B.
        • Russell S.J.
        • Peng K.W.
        Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
        Gene Ther. 2007; 14: 324-333
        • Liu C.
        • Russell S.J.
        • Peng K.W.
        Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
        Mol Ther. 2010; 18: 1155-1164
      1. Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma. ClinicalTrials.gov Identifier: NCT00450814. ClinicalTrials.gov website. http://clinicaltrials.gov/show/NCT00450814%20MC038C%20P30CA015083%20MC038C%2006-005263%20NCI-2009-01194%20NCT00450814. Updated March 20, 2014. Accessed April 14, 2014.

        • Mikhael J.R.
        • Dingli D.
        • Roy V.
        • et al.
        Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
        Mayo Clin Proc. 2013; 88: 360-376
        • Rajkumar S.V.
        • Jacobus S.
        • Callander N.S.
        • et al.
        • Eastern Cooperative Oncology Group
        Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial [published correction appears in Lancet Oncol. 2010;11(1):14].
        Lancet Oncol. 2010; 11: 29-37
        • Reeder C.B.
        • Reece D.E.
        • Kukreti V.
        • et al.
        Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
        Leukemia. 2009; 23: 1337-1341
        • Breitbach C.J.
        • Burke J.
        • Jonker D.
        • et al.
        Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
        Nature. 2011; 477: 99-102
        • Power A.T.
        • Wang J.
        • Falls T.J.
        • et al.
        Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.
        Mol Ther. 2007; 15: 123-130
        • Alcayaga-Miranda F.
        • Cascallo M.
        • Rojas J.J.
        • Pastor J.
        • Alemany R.
        Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies.
        Cancer Gene Ther. 2010; 17: 792-802
        • Guo Z.S.
        • Parimi V.
        • O'Malley M.E.
        • et al.
        The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.
        Gene Ther. 2010; 17: 1465-1475
        • Berry L.J.
        • Au G.G.
        • Barry R.D.
        • Shafren D.R.
        Potent oncolytic activity of human enteroviruses against human prostate cancer.
        Prostate. 2008; 68: 577-587
        • Bailey K.
        • Kirk A.
        • Naik S.
        • et al.
        Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.
        Plos One. 2013; 8: e73759